Japan as a Funding Source, page-9

@stockrock
Re : "the quantum of regenerative treatments , coupled with no real efficacy requirement, makes the market penetration significantly slower than what would be usually expected."

This is a point well made I think. It is one thing to get market approval for a product on safety and limited data on efficacy, but I wonder if it is quite another step again to get the experts to recommend their patients undertake a still relatively new treatment in such circumstances

What would be useful to hear, after this time in the market, are some meaningful reports of the outcomes patients are experiencing from the treatment.

Put simply, how many of the small numbers treated in Japan have benefitted from the treatment? That's the only way it's going to continue as a treatment option even if the market penetration remains slow.